Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Section for Clinical Neurogenetics, |
RCV000999493 | SCV001156134 | likely pathogenic | Epileptic encephalopathy | 2019-10-01 | no assertion criteria provided | research | |
OMIM | RCV001004652 | SCV001164100 | pathogenic | Developmental and epileptic encephalopathy, 84 | 2020-10-07 | no assertion criteria provided | literature only | |
Prevention |
RCV004758135 | SCV005363022 | uncertain significance | UGDH-related disorder | 2024-05-05 | no assertion criteria provided | clinical testing | The UGDH c.41A>G variant is predicted to result in the amino acid substitution p.Tyr14Cys. This variant was reported in the compound heterozygous state in an individual with developmental epileptic encephalopathy (Hengel et al 2020. PubMed ID: 32001716). This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |